Johnson & Johnson (JNJ) Stock Forecast & Price Target

Compare

149 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

JNJ Analyst Ratings

Moderate Buy

10 Buy

6 Hold

0 Sell

Based on 16 analysts giving stock ratings to

Johnson

& Johnson

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

JNJ Stock 12 Month Forecast

Average Price Target

€221.74

▲(7.23% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for Johnson & Johnson in the last 3 months. The average price target is €221.74 with a high forecast of €244.57 and a low forecast of €192.16. The average price target represents a 7.23% change from the last price of €206.80.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"129":"€129","158":"€158","187":"€187","216":"€216","245":"€245"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":244.5660476,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€244.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":221.7427946579,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€221.74</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":192.1590374,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€192.16</span>\n  </div></div>","useHTML":true}}],"tickPositions":[129,158,187,216,245],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,212.6,215.05892673846154,217.51785347692308,219.97678021538462,222.43570695384614,224.89463369230768,227.35356043076922,229.81248716923076,232.2714139076923,234.73034064615385,237.1892673846154,239.6481941230769,242.10712086153845,{"y":244.5660476,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,212.6,213.30329189676152,214.00658379352308,214.7098756902846,215.41316758704616,216.1164594838077,216.81975138056922,217.52304327733077,218.2263351740923,218.92962707085383,219.63291896761538,220.3362108643769,221.03950276113846,{"y":221.7427946579,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,212.6,211.02761826153846,209.4552365230769,207.88285478461538,206.31047304615385,204.7380913076923,203.16570956923076,201.59332783076923,200.0209460923077,198.44856435384614,196.8761826153846,195.30380087692308,193.73141913846152,{"y":192.1590374,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":152.866,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":142.261,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.757,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.17,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.816,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":140.903,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.391,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":155.401,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":161.43,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":176.701,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.766,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":192.994,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":212.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€244.57

Average Price Target€221.74

Lowest Price Target€192.16

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Louise Chen

Scotiabank

€231.46

Buy

11.93%

Upside

Reiterated

03/19/26

Analysts Are Bullish on These Healthcare Stocks: Immuneering (IMRX), Johnson & Johnson (JNJ)

Terence Flynn

Morgan Stanley

€228.84

Buy

10.66%

Upside

Reiterated

03/18/26

Early Icotyde Approval Strengthens Johnson & Johnson’s Immunology Growth Outlook and Multi‑Billion‑Dollar Potential

Asad Haider

Goldman Sachs

€231.46

Buy

11.93%

Upside

Reiterated

03/18/26

We arrive at our $265 12-month price target based on a 20x P/E multiple n on our Q5-Q8 EPS. Downside Risks: The ramp of new products could be slower than we expected, n resulting in less revenue to replenish declining products. Further uncertainty related to the Talc litigation could result in high-than-expected payouts and hamper multiples.

Matt Miksic

Barclays

€189.54→€204.39

Hold

-1.17%

Downside

Reiterated

03/18/26

Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (NASDAQ: XERS), CytomX Therapeutics (NASDAQ: CTMX) and Johnson & Johnson (NYSE: JNJ)

Morten Herholdt

HSBC

€231.46→€244.57

Buy

18.26%

Upside

Reiterated

03/17/26

Johnson & Johnson price target raised to $280 from $265 at HSBCJohnson & Johnson price target raised to $280 from $265 at HSBC

Danielle Antalffy

UBS

€214→€244.57

Buy

18.26%

Upside

Assigned

03/17/26

Johnson & Johnson price target raised to $280 from $245 at UBSJohnson & Johnson price target raised to $280 from $245 at UBS

Joanne Wuensch

Citi

€218.36→€239.33

Buy

15.73%

Upside

Assigned

03/12/26

Johnson & Johnson price target raised to $274 from $250 at CitiJohnson & Johnson price target raised to $274 from $250 at Citi

Chris Schott

J.P. Morgan

€196.53→€218.36

Hold

5.59%

Upside

Reiterated

03/05/26

Johnson & Johnson price target raised to $250 from $225 at JPMorganJohnson & Johnson price target raised to $250 from $225 at JPMorgan

Jason Gerberry

Bank of America Securities

€198.27→€220.98

Hold

6.86%

Upside

Reiterated

03/03/26

Balanced Outlook on Johnson & Johnson: Higher Oncology-Driven Estimates but Limited Upside Justify Hold Rating

Nico Chen

DBS

€209.63

Hold

1.37%

Upside

Reiterated

02/24/26

DBS Remains a Hold on Johnson & Johnson (JNJ)

Shagun Singh Chadha

RBC Capital

€209.63→€222.73

Buy

7.70%

Upside

Reiterated

02/03/26

Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX), UnitedHealth (NYSE: UNH) and Johnson & Johnson (NYSE: JNJ)

Vamil Divan

Guggenheim

€198.27→€209.63

Buy

1.37%

Upside

Reiterated

01/23/26

Johnson & Johnson price target raised to $240 from $227 at GuggenheimJohnson & Johnson price target raised to $240 from $227 at Guggenheim

Josh Jennings

TD Cowen

€193.91→€218.36

Buy

5.59%

Upside

Reiterated

01/22/26

Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN) and Johnson & Johnson (NYSE: JNJ)

Larry Biegelsen

Wells Fargo

€200.89→€209.63

Buy

1.37%

Upside

Reiterated

01/22/26

Johnson & Johnson price target raised to $240 from $230 at Wells FargoJohnson & Johnson price target raised to $240 from $230 at Wells Fargo

Rick Wise

Stifel Nicolaus

€179.06→€192.16

Hold

-7.08%

Downside

Reiterated

01/22/26

Stifel Nicolaus Sticks to Their Hold Rating for Johnson & Johnson (JNJ)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Louise Chen

Scotiabank

€231.46

Buy

11.93%

Upside

Reiterated

03/19/26

Analysts Are Bullish on These Healthcare Stocks: Immuneering (IMRX), Johnson & Johnson (JNJ)

Terence Flynn

Morgan Stanley

€228.84

Buy

10.66%

Upside

Reiterated

03/18/26

Early Icotyde Approval Strengthens Johnson & Johnson’s Immunology Growth Outlook and Multi‑Billion‑Dollar Potential

Asad Haider

Goldman Sachs

€231.46

Buy

11.93%

Upside

Reiterated

03/18/26

Matt Miksic

Barclays

€189.54→€204.39

Hold

-1.17%

Downside

Reiterated

03/18/26

Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (NASDAQ: XERS), CytomX Therapeutics (NASDAQ: CTMX) and Johnson & Johnson (NYSE: JNJ)

Morten Herholdt

HSBC

€231.46→€244.57

Buy

18.26%

Upside

Reiterated

03/17/26

Johnson & Johnson price target raised to $280 from $265 at HSBCJohnson & Johnson price target raised to $280 from $265 at HSBC

Danielle Antalffy

UBS

€214→€244.57

Buy

18.26%

Upside

Assigned

03/17/26

Johnson & Johnson price target raised to $280 from $245 at UBSJohnson & Johnson price target raised to $280 from $245 at UBS

Joanne Wuensch

Citi

€218.36→€239.33

Buy

15.73%

Upside

Assigned

03/12/26

Johnson & Johnson price target raised to $274 from $250 at CitiJohnson & Johnson price target raised to $274 from $250 at Citi

Chris Schott

J.P. Morgan

€196.53→€218.36

Hold

5.59%

Upside

Reiterated

03/05/26

Johnson & Johnson price target raised to $250 from $225 at JPMorganJohnson & Johnson price target raised to $250 from $225 at JPMorgan

Jason Gerberry

Bank of America Securities

€198.27→€220.98

Hold

6.86%

Upside

Reiterated

03/03/26

Balanced Outlook on Johnson & Johnson: Higher Oncology-Driven Estimates but Limited Upside Justify Hold Rating

Nico Chen

DBS

€209.63

Hold

1.37%

Upside

Reiterated

02/24/26

DBS Remains a Hold on Johnson & Johnson (JNJ)

Shagun Singh Chadha

RBC Capital

€209.63→€222.73

Buy

7.70%

Upside

Reiterated

02/03/26

Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX), UnitedHealth (NYSE: UNH) and Johnson & Johnson (NYSE: JNJ)

Vamil Divan

Guggenheim

€198.27→€209.63

Buy

1.37%

Upside

Reiterated

01/23/26

Johnson & Johnson price target raised to $240 from $227 at GuggenheimJohnson & Johnson price target raised to $240 from $227 at Guggenheim

Josh Jennings

TD Cowen

€193.91→€218.36

Buy

5.59%

Upside

Reiterated

01/22/26

Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN) and Johnson & Johnson (NYSE: JNJ)

Larry Biegelsen

Wells Fargo

€200.89→€209.63

Buy

1.37%

Upside

Reiterated

01/22/26

Johnson & Johnson price target raised to $240 from $230 at Wells FargoJohnson & Johnson price target raised to $240 from $230 at Wells Fargo

Rick Wise

Stifel Nicolaus

€179.06→€192.16

Hold

-7.08%

Downside

Reiterated

01/22/26

Stifel Nicolaus Sticks to Their Hold Rating for Johnson & Johnson (JNJ)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Johnson & Johnson

3 Months

xxx

Success Rate

23/26 ratings generated profit

Average Return

+5.05%

assigned a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 88.46% of your transactions generating a profit, with an average return of +5.05% per trade.

1 Year

Danielle AntalffyUBS

Success Rate

26/26 ratings generated profit

Average Return

+13.75%

assigned a buy rating 4 days ago

Copying Danielle Antalffy's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +13.75% per trade.

2 Years

xxx

Success Rate

25/25 ratings generated profit

Average Return

+50.22%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +50.22% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

JNJ Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, JNJ has received 31 Buy Ratings, 15 Hold Ratings, and 0 Sell Ratings. JNJ average Analyst price target in the past 3 months is 221.74.

Each month's total comprises the sum of three months' worth of ratings.

JNJ Financial Forecast

JNJ Earnings Forecast

Next quarter’s earnings estimate for JNJ is €2.34 with a range of €1.86 to €2.53. The previous quarter’s EPS was €2.14. JNJ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year JNJ has Performed in-line its overall industry.

JNJ Sales Forecast

Next quarter’s sales forecast for JNJ is €20.57B with a range of €19.53B to €21.12B. The previous quarter’s sales results were €21.41B. JNJ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year JNJ has Performed in-line its overall industry.

JNJ Stock Forecast FAQ

What is DE:JNJ’s average 12-month price target, according to analysts?

Based on analyst ratings, Johnson & Johnson’s 12-month average price target is 221.74.

What is DE:JNJ’s upside potential, based on the analysts’ average price target?

Johnson & Johnson has 7.23% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Johnson & Johnson a Buy, Sell or Hold?

Johnson & Johnson has a consensus rating of Moderate Buy, which is based on 10 buy ratings, 6 hold ratings and 0 sell ratings.

What is Johnson & Johnson’s share price target?

The average share price target for Johnson & Johnson is 221.74. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €244.57 ,and the lowest forecast is €192.16. The average share price target represents 7.23% Increase from the current price of €206.8.

What do analysts say about Johnson & Johnson?

Johnson & Johnson’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of Johnson & Johnson?

To buy shares of DE:JNJ, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Johnson & Johnson (JNJ) Stock Forecast & Price Target

JNJ Analyst Ratings

JNJ Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Johnson & Johnson

JNJ Analyst Recommendation Trends

JNJ Financial Forecast

JNJ Earnings Forecast

JNJ Sales Forecast

JNJ Stock Forecast FAQ

Detailed List of Analyst Forecasts